LENZ Therapeutics, Inc.

NASDAQ:LENZ

Biotechnology

Healthcare
$3.21 -6.62%

-$0.42 today

Market cap
$100.86M
Beta
1.47
P/E (TTM)
-1.7
EPS (TTM)
-$3.48
52W Low $5.85High $50.40

Volume 0.62M

Average 0.89M

LENZ Income Tax Expense

Income taxes recognized for the period, including current and deferred tax.

LENZ Therapeutics, Inc.NASDAQ: LENZ

Income Tax Expense · Q1 FY2026 · quarter ended Mar 2026

Income tax expense remains negative

Q1 FY2026 income tax expense was $0, compared with $0 a year earlier. Trailing-twelve-month income tax expense was $502K. Over 3 fiscal years it compounded at +13.1% a year.

Context

  • Income tax expense amounted to 2.6% of revenue in FY2025.
  • Income tax expense increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly income tax expense holds near $0 or moves back toward the trailing-twelve-month quarterly average of $125.5K.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$0-100.0% QoQ
Last fiscal yearDec 2025
$502K+50100.0% YoY
LTMMar 2026
$502K+50100.0% YoY
Income Tax Expense past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year+50100.0%——
3-year CAGR+13.1%——
5-year CAGR——
10-year CAGR——

Income Tax Expense history

USD · from the income statement

Latest · FY2025
502K USD
Year-over-year change
+50100.0%

Income Tax Expense vs competitors

How LENZ compares with its peers on the latest reported figures

  • Peers report in different currencies, so income tax expense is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +50100.0% is the highest of 5, against a peer median of -3.9%.
  • Income tax expense amounts to 2.4% of revenue for LENZ, versus a peer median of 0.0%.
LENZ Competitors
Income Tax Expense for LENZ and competitors
Company Period LTM YoY 3-year CAGR% of revenue
LENZLENZ Therapeutics, Inc.LTM Mar 2026$502K USD+50100.0%+13.1%2.4%
NBTXNanobiotix S.A.FY2025€3K EUR-97.0%-33.1%0.0%
TYRATyra Biosciences, Inc.LTM Mar 2026$0 USD———
GHRSGH Research PLCLTM Mar 2026$0 USD———
SVRASavara Inc.LTM Mar 2026$0 USD———
ABUSArbutus Biopharma CorporationLTM Mar 2026$0 USD——0.0%
PRMEPrime Medicine, Inc.LTM Mar 2026$0 USD+100.0%—0.0%
GERNGeron CorporationLTM Mar 2026$0 USD——0.0%
RZLTRezolute, Inc.LTM Mar 2026$0 USD———
SPRYARS Pharmaceuticals, Inc.LTM Mar 2026-$80K USD-127.8%—0.1%
MRVIMaravai LifeSciences Holdings, Inc.LTM Jun 2026-$408K USD+89.3%—0.2%
Peer median (excluding LENZ) —-3.9%-33.1%0.0%

Competitors are the stored peer set for LENZ. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue015M0019.09M
Cost of Revenue734K0058K705K
Gross Profit(734K)15M0(58K)18.38M
Gross Margin—100.0%——96.3%
Research & Development37.93M21.13M59.5M29.8M18.67M
Selling, General & Admin21.78M4.36M12.93M28.75M90.85M
Operating Expenses59.71M25.48M72.43M58.55M109.52M
Depreciation & Amortization734K8K15K58K287K
EBITDA(70.03M)(10.46M)(70.13M)(49.71M)(81.34M)
EBITDA Margin—-69.7%——-426.1%
Operating Income(60.44M)(10.48M)(72.43M)(58.61M)(91.14M)
Operating Margin—-69.9%——-477.5%
Interest Income002.19M8.55M9.76M
Interest Expense00000
Other Income / Expenses(10.32M)19K2.28M8.84M9.51M
Income Before Tax(70.76M)(10.46M)(70.15M)(49.77M)(81.63M)
Pre-Tax Margin—-69.8%——-427.6%
Income Tax Expense0347K(179K)1K502K
Net Income(70.76M)(10.81M)(69.97M)(49.77M)(82.13M)
Net Margin—-72.1%——-430.3%
EPS (Basic)(8.54)(12.89)(15.30)(2.34)(2.85)
EPS (Diluted)(8.54)(12.89)(15.30)(2.34)(2.85)
Weighted Avg Shares8.29M7.84M8.15M21.28M28.81M
Weighted Avg Shares (Diluted)8.29M7.84M8.15M21.28M28.81M

LENZ Therapeutics, Inc.

NASDAQ:LENZ

Intrinsic Alpha fair value

Locked

Current Price

$3.21

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.